Article
B cells and tertiary lymphoid structures promote immunotherapy response.
Nature - 1 Jan 2020
Helmink Beth A, Reddy Sangeetha M, Gao Jianjun, Zhang Shaojun, Basar Rafet, Thakur Rohit, Yizhak Keren, Sade-Feldman Moshe, Blando Jorge, Han Guangchun, Gopalakrishnan Vancheswaran, Xi Yuanxin, Zhao Hao, Amaria Rodabe N, Tawbi Hussein A, Cogdill Alex P, Liu Wenbin, LeBleu Valerie S, Kugeratski Fernanda G, Patel Sapna, Davies Michael A, Hwu Patrick, Lee Jeffrey E, Gershenwald Jeffrey E, Lucci Anthony, Arora Reetakshi, Woodman Scott, Keung Emily Z, Gaudreau Pierre-Olivier, Reuben Alexandre, Spencer Christine N, Burton Elizabeth M, Haydu Lauren E, Lazar Alexander J, Zapassodi Roberta, Hudgens Courtney W, Ledesma Deborah A, Ong SuFey, Bailey Michael, Warren Sarah, Rao Disha, Krijgsman Oscar, Rozeman Elisa A, Peeper Daniel, Blank Christian U, Schumacher Ton N, Butterfield Lisa H, Zelazowska Monika A, McBride Kevin M, Kalluri Raghu, Allison James, Petitprez Florent, Fridman Wolf Herman, Sautès-Fridman Catherine, Hacohen Nir, Rezvani Katayoun, Sharma Padmanee, Tetzlaff Michael T, Wang Linghua, Wargo Jennifer A
Abstract excerpt
Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers1-10 and strategies to augment clinical response have largely focused on the T cell compartment. However, other immune subsets may also contribute to anti-tumour immunity11-15, although these have been less well-studied in ICB treatment16. A previously conducted neoadjuvant ICB trial in patients with...
Read the complete abstract on PubMed